Sophia Genetics (SOPH) and Complete Genomics said Tuesday they are collaborating to expand access to precision oncology testing.
Sophia Genetics will integrate its MSK-IMPACT and MSK-ACCESS applications with sequencing technology from Complete Genomics to deliver an integrated, sample-to-report workflow for cancer genomic profiling, the companies said.
Shares of Sophia Genetics were up over 3% in recent trading.
Price: 4.45, Change: +0.10, Percent Change: +2.18
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.